公开(公告)号：US20180256595A1

公开(公告)日：2018-09-13

申请号：US15755700

申请日：2016-08-31

Applicant: KOWA COMPANY, LTD.

Inventor： Kenji Kawamata ,  Kazushi Maruo ,  Hideki Suganami

IPC: A61K31/551 ,  A61P27/06

CPC classification number: A61K31/551 ,  A61K45/00 ,  A61P27/06

Abstract: The present invention pertains to a drug available for long-term continuous administration for preventing or treating glaucoma or ocular hypertension, said drug showing no decrease in efficacy during long-term administration and exhibiting a stable ocular hypotensive effect. The present invention pertains to a therapeutic agent for glaucoma or ocular hypertension that is to be continuously administered for a long period of time, said drug comprising an Rho kinase inhibitor, more specifically, to a therapeutic agent comprising an Rho kinase inhibitor for treating glaucoma or ocular hypertension in a patient suffering from glaucoma or ocular hypertension who has been administered with a therapeutic agent comprising the Rho kinase inhibitor for treating glaucoma or ocular hypertension continuously over a definite period of time and needs a further enhanced ocular hypotensive effect.